Capital Advisors Ltd. LLC Has $680,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Capital Advisors Ltd. LLC grew its stake in Amgen Inc. (NASDAQ:AMGN) by 3.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,175 shares of the medical research company’s stock after buying an additional 77 shares during the period. Capital Advisors Ltd. LLC’s holdings in Amgen were worth $680,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Capital International Investors lifted its holdings in Amgen by 547.8% in the 1st quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock worth $1,991,738,000 after purchasing an additional 5,923,915 shares during the last quarter. Norges Bank bought a new position in shares of Amgen in the fourth quarter valued at approximately $1,556,912,000. Vanguard Group Inc. raised its position in shares of Amgen by 6.2% in the first quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock valued at $14,809,720,000 after purchasing an additional 3,045,657 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Amgen by 137.1% in the first quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company’s stock worth $676,984,000 after buying an additional 1,377,007 shares during the last quarter. Finally, Capital Wealth Planning LLC boosted its holdings in shares of Amgen by 28,684.1% during the 1st quarter. Capital Wealth Planning LLC now owns 833,300 shares of the medical research company’s stock worth $236,924,000 after buying an additional 830,405 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ AMGN traded up $4.27 during trading on Friday, reaching $328.80. 1,771,092 shares of the company traded hands, compared to its average volume of 2,582,902. Amgen Inc. has a 1-year low of $248.38 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The stock’s 50 day moving average price is $322.70 and its two-hundred day moving average price is $299.54. The company has a market cap of $176.38 billion, a price-to-earnings ratio of 46.97, a P/E/G ratio of 2.78 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter last year, the company earned $5.00 earnings per share. The business’s revenue was up 20.1% on a year-over-year basis. As a group, analysts anticipate that Amgen Inc. will post 19.5 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Wall Street Analyst Weigh In

Several brokerages recently commented on AMGN. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. William Blair raised Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Argus increased their target price on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Finally, TD Cowen increased their price objective on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Eleven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.